Rethinking Antipsychotic Formulary Policy

Rethinking antipsychotic formulary policy.

In this commentary, we review recent research suggesting that (a) second-generation antipsychotics (SGAs) may be no more effective than first-generation antipsychotics (FGAs), (b) the reduced risk of EPS and tardive dyskinesia with SGAs is more weakly supported by the research literature than has been appreciated, and (c) benefits may be offset by greater metabolic risks of some SGAs and their ...

The diffusion of new antipsychotic medications and formulary policy.

Spending on antipsychotic medications continues to escalate as new products such as atypicals are increasingly used to treat schizophrenia and other conditions. Given that per person spending on behavioral health benefits is shrinking while spending on pharmaceutical products is increasing, the psychotropic portion of mental health expenditures is likely to continue to increase in the future. T...

Rethinking aspects of AIDS policy.

RETHINKING INDUSTRIAL POLICY bruegel policybrief

Our new evidence on the effectiveness of government intervention should lead policymakers to revisit industrial policy. If the EU is to grow and compete globally, there is a case for the European Commission to allow national or EU sectoral aid, if it is appropriately designed and governed to encourage the redirection of innovation and production. Horizontal support and sectoral aid for upstream...

Rethinking mental health policy-making in Iran: a letter to the editor